IRIS - Res&Arch Institutional Research Information System - Research & Archive

METRO, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.987
NA - Nord America 3.109
EU - Europa 2.129
SA - Sud America 1.293
AF - Africa 154
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 10.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.939
SG - Singapore 1.608
BR - Brasile 958
CN - Cina 593
VN - Vietnam 564
IT - Italia 434
HK - Hong Kong 412
RU - Federazione Russa 341
IE - Irlanda 299
KR - Corea 261
FR - Francia 231
DE - Germania 209
AR - Argentina 138
BD - Bangladesh 124
FI - Finlandia 117
IN - India 103
SE - Svezia 98
GB - Regno Unito 88
MX - Messico 63
CA - Canada 62
RO - Romania 59
EC - Ecuador 58
AT - Austria 46
ID - Indonesia 46
ZA - Sudafrica 46
TR - Turchia 40
IQ - Iraq 39
CO - Colombia 34
NL - Olanda 34
UA - Ucraina 34
JP - Giappone 32
PL - Polonia 32
MA - Marocco 31
PY - Paraguay 28
VE - Venezuela 28
PK - Pakistan 26
ES - Italia 23
SA - Arabia Saudita 20
CL - Cile 18
UZ - Uzbekistan 18
DZ - Algeria 17
JO - Giordania 16
EG - Egitto 15
PE - Perù 12
TN - Tunisia 12
CH - Svizzera 11
HR - Croazia 11
OM - Oman 11
JM - Giamaica 10
PH - Filippine 10
UY - Uruguay 10
LB - Libano 9
LT - Lituania 9
MY - Malesia 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
CZ - Repubblica Ceca 7
AL - Albania 6
CR - Costa Rica 6
ET - Etiopia 6
HN - Honduras 6
KE - Kenya 6
KZ - Kazakistan 6
AZ - Azerbaigian 5
BE - Belgio 5
HU - Ungheria 5
NI - Nicaragua 5
PS - Palestinian Territory 5
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
NP - Nepal 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
GR - Grecia 3
LV - Lettonia 3
MT - Malta 3
NG - Nigeria 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
CM - Camerun 2
DK - Danimarca 2
EU - Europa 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
MK - Macedonia 2
RS - Serbia 2
SN - Senegal 2
SO - Somalia 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BF - Burkina Faso 1
BS - Bahamas 1
Totale 10.661
Salva come PNG Salva come JPEG
Città #
Singapore 1.076
Hong Kong 411
San Jose 349
Chandler 331
Dublin 298
Ashburn 266
Seoul 260
Ho Chi Minh City 187
Perugia 167
Lauterbourg 155
Beijing 127
Boardman 125
Moscow 125
Piscataway 124
Santa Clara 112
San Mateo 103
Hanoi 97
New York 93
São Paulo 93
Munich 92
Los Angeles 73
Altamura 72
Lawrence 58
Medford 58
Princeton 58
Bucharest 57
Dong Ket 57
Hefei 48
Turku 44
Helsinki 43
Wilmington 41
The Dalles 35
Dallas 31
Andover 30
Rio de Janeiro 30
Frankfurt am Main 29
Tokyo 29
Mexico City 28
Nuremberg 28
Orem 27
Redmond 27
Brooklyn 26
Da Nang 25
Brasília 24
Warsaw 24
Guayaquil 22
Johannesburg 22
Montreal 21
Stockholm 21
Haiphong 20
Denver 19
Atlanta 18
Baghdad 18
Poplar 18
Belo Horizonte 17
Guarulhos 17
Buenos Aires 16
Falkenstein 16
San Paolo di Civitate 16
Amman 15
Saint Petersburg 15
Tashkent 15
Biên Hòa 14
Boston 14
Chennai 14
Curitiba 14
London 14
Milan 14
Vienna 14
Amsterdam 13
Chicago 13
Council Bluffs 13
Guangzhou 13
Manchester 13
Quito 13
Houston 12
Mumbai 12
Santo André 12
Bắc Ninh 11
Caracas 11
Hải Dương 11
Osijek 11
Rome 11
Shanghai 11
Thái Bình 11
Ankara 10
Cairo 10
San Francisco 10
Seattle 10
Ann Arbor 9
Arezzo 9
Asunción 9
Des Moines 9
Dhaka 9
Jeddah 9
Lahore 9
Norwalk 9
Toronto 9
Boydton 8
Bắc Giang 8
Totale 6.325
Salva come PNG Salva come JPEG
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 193
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 140
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 129
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 120
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 119
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 118
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 114
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 109
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 108
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 108
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. 107
Non-coding RNAs in lung cancer 104
Osimertinib 98
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 98
Future options for ALK-positive non-small cell lung cancer 96
Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma 96
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 96
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 96
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 96
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 94
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles 94
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 94
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 92
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 92
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 90
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 90
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 90
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 90
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 89
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 89
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 86
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 86
Sacrum colon-rectal cancer metastasis: Microwave ablation for palliative pain treatment 86
Inflammatory markers as prognostic factors of survival in patients affected by hepatocellular carcinoma undergoing transarterial chemoembolization 86
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 83
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 82
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 82
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 82
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 81
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 81
Ercc1 Mrna Expression and Kras Mutation Status In Egfr Wild Type (wt) Advanced Non-small Cell Lung Cancer (nsclc) Patients 78
Tumour infiltrating lymphocytes (TILs) and PD-L1 expression in malignant pleural mesothelioma. 77
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study 77
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study 76
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 76
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 76
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 76
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 75
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 74
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) 74
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 73
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 73
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 73
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 72
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis 71
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 71
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 70
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 70
Perspectives on salvage therapy for non-small-cell lung cancer 68
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.] 68
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care 68
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 68
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 68
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 67
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 67
Emerging drugs for small cell lung cancer - an update 67
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 66
Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas 66
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 64
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 63
Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? 63
Clinical experience with gefitinib: an update 63
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 63
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 62
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 62
Development of gemcitabine in non-small cell lung cancer: the Italian contribution 61
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 61
Advances on EGFR mutation for lung cancer 61
Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC 59
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 58
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 58
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC 58
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors 57
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 57
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 56
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 55
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 55
Prognostic Role of Expression Levels of Fabp3, H19, Tfpi2, Akr1b10 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients 55
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer 54
2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC 54
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 53
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies 53
Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance 52
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) 52
Prognostic role of expression levels of FABP3 and AKR1B10 genes in adenocarcinoma stage I patients. 52
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer 51
Non-small-cell lung cancer: how to manage RET-positive disease 51
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) 51
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines 49
Totale 7.836
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.984
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.984
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202160 0 0 0 0 0 0 0 0 0 0 0 60
2021/2022498 9 80 3 17 6 6 1 146 30 49 65 86
2022/20231.023 59 214 23 82 95 84 0 38 386 2 30 10
2023/2024459 23 43 30 9 2 3 107 11 26 13 93 99
2024/20251.688 24 96 66 53 139 75 44 125 179 55 579 253
2025/20266.738 399 735 617 1.385 668 366 823 371 570 478 188 138
Totale 10.990